Search Results - Haifa Kathrin Al‐Ali

Refine Results
  1. 1
    The role of hypomethylating agents in the treatment of elderly patients with AML

    The role of hypomethylating agents in the treatment of elderly patients with AML by Haifa Kathrin Al‐Ali, Nadja Jaekel, Dietger Niederwieser

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Case Report: Influence of BRCA1 germline mutation on treatment-related morbidity of a non-seminomatous germ cell tumor patient

    Case Report: Influence of BRCA1 germline mutation on treatment-related morbidity of a non-seminomatous germ cell tumor patient by Bruno Griesler, Susann Schulze, Thomas Kegel, Christine Dierks, Pablo Villavicencio‐Lorini, Markus Eszlinger, Haifa Kathrin Al‐Ali, Nadja Jaekel

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Mesenchymal Stem Cells Remain Host-Derived Independent of the Source of the Stem-Cell Graft and Conditioning Regimen Used

    Mesenchymal Stem Cells Remain Host-Derived Independent of the Source of the Stem-Cell Graft and Conditioning Regimen Used by Kristina Bartsch, Haifa Kathrin Al‐Ali, Annette Reinhardt, Christina Franke, Michael Hudecek, Manja Kamprad, Sabine Tschiedel, Michael Cross, Dietger Niederwieser, Chiara Gentilini

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

    The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies by Vikas Gupta, Claire Harrison, Elizabeth O. Hexner, Haifa Kathrin Al‐Ali, Lynda Foltz, Michael T. Montgomery, William Sun, P. Gopalakrishna, H. Kantarjian, Srđan Verstovšek

    Published 2016
    Get full text
    Carta
    Save to List
    Saved in:
  5. 5
    How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024

    How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024 by Martin Grießhammer, Haifa Kathrin Al‐Ali, Jan‐Niklas Eckardt, Michael Fiegl, Joachim R. Göthert, Kathleen Jentsch‐Ullrich, Steffen Koschmieder, Hans Michael Kvasnicka, Andreas Reiter, Burkhard Schmidt, Florian H. Heidel

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

    Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority by Thomas G.P. Bumm, Christel Müller, Haifa Kathrin Al‐Ali, Knut Krohn, Patricia Shepherd, Erika Schmidt, Sabine Leiblein, Christina Franke, Evelin Hennig, Thomas Friedrich, Reiner Krahl, Dietger Niederwieser, Michael W. Deininger

    Published 2003
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

    Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study by Vikas Gupta, Martin Grießhammer, Bruno Martino, Lynda Foltz, Renato Tavares Daher, Haifa Kathrin Al‐Ali, Pilar Giraldo, Paola Guglielmelli, Elza Lomaia, Catherine Bouard, Carole Paley, Ranjan Tiwari, Evren Zor, Pia Raanani

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

    Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis by Claire Harrison, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Heinz Gisslinger, L. Knoops, Francisco Cervantes, Mark M. Jones, Kang Sun, Mari McQuitty, Viktoriya Stalbovskaya, P. Gopalakrishna, Tiziano Barbui

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hämato-Onkologie OSHO-53 phase II study

    Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radi... by Michael Montemurro, Thomas Kiefer, Frank Schüler, Haifa Kathrin Al‐Ali, H-H. Wolf, Regina Herbst, A. Haas, K. Helke, Anja Theilig, Christian Lotze, Carsten Hirt, D Niederwieser, M. Schwenke, William Krüger, Gottfried Dölken

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

    JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis by Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Heinz Gisslinger, Roger J. Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah Hunter, Richard Levy, Laurent Knoops, Francisco Cervantes, Alessandro M. Vannucchi, Tiziano Barbui, Giovanni Barosi

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

    Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis by Francisco Cervantes, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Andres Sirulnik, Viktoriya Stalbovskaya, Mari McQuitty, Deborah Hunter, Richard S. Levy, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Claire Harrison, Laurent Knoops, Heinz Gisslinger

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

    Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosi... by Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al‐Ali, Renato Tavares Daher, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Martin Grießhammer, Paola Guglielmelli, Catherine Bouard, Carole Paley, Ranjan Tiwari, Alessandro M. Vannucchi

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

    FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of th... by Susanne Isfort, Nikolas von Bubnoff, Haifa Kathrin Al‐Ali, Heiko Becker, Thorsten Oliver Götze, Philipp le Coutre, Martin Grießhammer, Claudia Moskwa, Luisa Wohn, Johanna Riedel, Francesca Palandri, Kirsi Manz, Andreas Hochhaus, Konstanze Döhner, Florian H. Heidel

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

    A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence by Ayalew Tefferi, Haifa Kathrin Al‐Ali, Giovanni Barosi, Timothy Devos, Heinz Gisslinger, Qingwu Jiang, Jean‐Jacques Kiladjian, Ruben A. Mesa, Francesco Passamonti, Vincent Ribrag, Gary J. Schiller, Alessandro M. Vannucchi, D Zhou, D Reiser, Judy Zhong, Gale Rp

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

    Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study by Francisco Cervantes, David M. Ross, Atanas Radinoff, Francesca Palandri, Alexandr Myasnikov, Alessandro M. Vannucchi, Pierre Zachée, Heinz Gisslinger, Norio Komatsu, Lynda Foltz, Francesco Mannelli, Francesco Passamonti, Geralyn Gilotti, Islam Sadek, Ranjan Tiwari, Evren Zor, Haifa Kathrin Al‐Ali

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

    Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP... by Haifa Kathrin Al‐Ali, Martin Grießhammer, Philipp le Coutre, Cornelius F. Waller, A. M. Liberati, Philippe Schafhausen, Renato Tavares Daher, Pilar Giraldo, Lynda Foltz, Pia Raanani, Vikas Gupta, Bayane Tannir, Julian Perez Ronco, Jaya Ghosh, B. Martino, Alessandro M. Vannucchi

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care by Hartmut Döhner, Anna Dolnik, Lin Tang, John F. Seymour, Mark D. Minden, Richard M. Stone, Teresa Bernal, Haifa Kathrin Al‐Ali, Valeria Santini, Paresh Vyas, C.L. Beach, Kyle J. MacBeth, Barry Skikne, S. Songer, Nora Tu, Lars Bullinger, Hervé Dombret

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib <i>versus</i> best available therapy

    Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib <i>versus</i> best available therapy by Claire Harrison, Ruben A. Mesa, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Heinz Gisslinger, Laurent Knoops, Margaret Squier, Andres Sirulnik, Estella Mendelson, Xiaolei Zhou, Catherine Copley‐Merriman, Deborah Hunter, Richard S. Levy, Francisco Cervantes, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

    Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Ly... by Michael Herold, Antje Haas, Stefanie Srock, Sabine Neser, Haifa Kathrin Al‐Ali, Andreas Neubauer, Gottfried Dölken, Ralph Naumann, Wolfgang Knauf, Mathias Freund, Robert Rohrberg, K. Höffken, Astrid Franke, T. H. Ittel, E. Kettner, Ursula Haak, Ulrich Mey, C. Klinkenstein, Michael Aβmann, Ullrich von Grünhagen

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

    Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study by Uwe Platzbecker, Katharina S. Götze, Philipp Kiewe, Ulrich Germing, Karin Mayer, Markus P. Radsak, Thomas Wolff, Jöerg Chromik, Katja Sockel, Uta Oelschlägel, Detlef Haase, Thomas Illmer, Haifa Kathrin Al‐Ali, Gerda Silling, Joseph G. Reynolds, Xiaosha Zhang, Kenneth M. Attie, Jeevan K. Shetty, Aristoteles Giagounidis

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: